migraine

  1. Pipeline saved with cheap buyout

    seems the executive teams for Biogen and Zosano have been meeting a lot as of late.. backfilling that empty pipeline. apparently a quarter of funds earmarked for the 1 billion stock buyback will actually go towards acquiring this migraine therapy in a cash and stock deal. Being scooped up...
  2. Lilly in the migraine drug race

    http://alph.st/bf3c0558 Lilly joins the migraine drug race with Novartis and Amgen, as FDA accepts to review Lilly's Galcanezumab. Already, Teva filed a lawsuit in October 2017, seeking to block Lilly's migraine drug to market in the U.S. The size of the migraine market is expected to more than...